Pharmacological antagonism of the incretin system protects against diet-induced obesity

by Berit Svendsen, Megan E. Capozzi, Jingjing Nui, Sarah A. Hannou, Brian Finan, Jacqueline Naylor, Peter Ravn, David A. D'Alessio, Jonathan E. Campbell
Published 2020-02-01

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

by Tamer Coskun, Kyle W. Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B. Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Uma Kuchibhotla, Julie S. Moyers, Charles T. Benson, Ruth E. Gimeno, David A. D'Alessio, Axel Haupt
Published 2018-12-01

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

by Francis S. Willard, Jonathan D. Douros, Maria B.N. Gabe, Aaron D. Showalter, David B. Wainscott, Todd M. Suter, Megan E. Capozzi, Wijnand J.C. van der Velden, Cynthia Stutsman, Guemalli R. Cardona, Shweta Urva, Paul J. Emmerson, Jens J. Holst, David A. D’Alessio, Matthew P. Coghlan, Mette M. Rosenkilde, Jonathan E. Campbell, Kyle W. Sloop
Published 2020-09-01